Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE The mRNA expression levels of OVCA1, cyclin D1 and p16 in cervical cancer and normal cervix cells were detected using real-time polymerase chain reaction. 28521400 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE 1) To analyze the expression of Ki-67, p53 and p16(INK4a) in cervical cancer, 2) to correlate the relative expression of these proteins as well as clinical parameters with the stage of disease, and 3) to determine the HPV DNA prevalence and subtype distribution. 23505442 2013
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Role of p16 testing in cervical cancer screening among HIV-infected women. 29023464 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE All 3 cases of vulvar carcinoma showing homozygous deletions of p16INK4 and p15INK4B were at advanced clinical stage (stage III-IV), while all 7 cases of cervical carcinoma and 2 cases of ovarian carcinoma showing homozygous deletion of p16INK4 were at early stage (stage I-II). 9159345 1997
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE By overlapping these dysregulated genes, we found that three genes, including CDKN2A, IL1R2 and RFC4, were not only changed in HSIL, but also significantly changed in SCC, indicating that their dysregulation may contribute to cervical cancer development. 28341182 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Our findings suggest that FISH detection for p16ink4a is a potential alternative triage for high-risk HPV positive women in cervical cancer screening. 20926123 2011
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE The deletion frequency of P16 and RB1 increased significantly with CACX progression. 27458253 2016
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 PosttranslationalModification disease BEFREE The promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A was investigated by using a methylation-specific polymerase chain reaction in 53 specimens of cervical cancer (42 squamous cell carcinoma, 11 adenocarcinoma), 22 specimens of intraepithelial neoplasia tissues, and 24 control normal cervical tissue specimens. 23494221 2014
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE To conduct a comprehensive mapping of the genomic DNA methylation in CDKN2A, which codes for the p16(INK4A) and p14(ARF) proteins, and 14 of the most promising DNA methylation marker candidates previously reported to be associated with progression of low-grade cervical intraepithelial neoplasia (CIN1) to cervical cancer. 27401842 2016
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE p16(INK4A) (p16) has been suggested to be an early biomarker for the detection of cervical cancer. 17369842 2007
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE Hypermethylation of promoter regions of the APC1A and p16INK4a genes in relation to prognosis and tumor characteristics in cervical cancer patients. 21674126 2011
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression disease BEFREE Immunohistochemical expression of p16 in ovarian tumors can guide the diagnosis of metastasis from HPV-related cervical cancer, but p16 positivity is nonspecific. 31014281 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. 21228361 2011
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE HNRNPA1 (92%) and p16 (91%) presented the two highest diagnostic accuracies for cervical carcinoma, which were superior to those of SRSF3 (75%), SRSF1-HMws (72%), CEA (72%), SCCA (59%), and SRSF1-Total (55%). 27984373 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression disease BEFREE Thus, it seems that P16 inactivation may be associated with the development of some uterine cervical carcinoma. 12911724 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE Correlation between methylation status of p16 gene and poor menstrual hygiene was significant (p=0.006), high parity cases showed methylation of p16 gene (p=0.031) with increased risk up to 1.86 times for cervical cancer and smoking was a strong risk factor associated with cervical cancer. 27644676 2016
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression disease BEFREE To investigate the expression of p16(INK4a) in cervical carcinoma and its relation to the transition of carcinoma in situ to invasive carcinoma, and its role in recurrence of cervical lesions as well, a series of 90 patients with cervical carcinoma (49 with in situ lesion and 41 with invasive lesion) were selected from July 2001 and September 2002. 19100258 2009
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 PosttranslationalModification disease BEFREE Status of p16(INK4a) and E-cadherin gene promoter methylation in Moroccan patients with cervical carcinoma. 20112504 2009
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE p16INK4a is a highly sensitive marker of cervical intraepithelial neoplasia and cervical cancer. 18958930 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE To investigate the HPV-independent pathway of carcinogenesis in cases of gastric-type AC, we investigated the common high-risk HPV (hr-HPV) status in 52 nonsquamous cell carcinomas, using a PCR-based typing method and immunohistochemistry of p16INK4a (a cyclin-dependent kinase inhibitor that is overexpressed in both cancerous and precancerous cervical tissue, making it an ideal biomarker for cervical cancer cases). 20829441 2010
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE We conclude that both markers; p16INK4A and p14ARF are complementary and should be evaluated jointly in order to improve the accuracy of cytological diagnosis of cervical cancer. 22072122 2012
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE The knowledge about human papillomavirus as a causative agent of cervical cancer has accumulated over the last decades has opened the possibility to improve the existing prevention strategies and screening practices. p16 has amply been applied on cytologic samples and has been shown to be a promising marker especially in identification of high-grade dysplasia. 19941372 2010
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE To evaluate the value of the combination of p16 and HPV detection in the screening for cervical cancer. 16494930 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE And SNP at C580T of p16 gene was found to be negatively associated with the risk of cervical cancer (P=0.0004, OR=0.04, 95% CI=0.002-0.63). p16 (540C/580T) has emerged as a major risk haplotype (P=0.033, OR=1.47, 95% CI=1.05-2.07) whereas p16 (540G/580T) as a chief protective haplotype (P=0.014, OR=0.39, 95% CI=0.18-0.83) for the development of cervical cancer among Indian women. 21567202 2012
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE Methylation of the p16(INK4a) gene occurs early in the development of cervical cancer. 25579180 2015